Hematopoietic Stem Cells from Human Term Placenta

描述（由申请人提供）：不幸的是，只有一小部分需要造血干细胞移植的患者可以从这种挽救生命的治疗中受益。成功的移植需要足够数量的免疫匹配的干细胞，这是一种非常有限的资源。新生儿出生后采集的脐带血是造血干细胞和祖细胞（HSPC）的有效来源。然而，虽然脐带血用于移植的利用正在扩大，但每个单位的细胞含量严重限制了其应用。此外，超过一半的脐带血采集单位没有储存在公共脐带血库，因为干细胞计数不保证储存供未来使用。PlaSalus旨在通过使用人类足月胎盘来定义克服这些限制的方案。使用新技术，我们建议开发胎盘作为HSPC的新来源，以增加和大幅改善目前可用于骨髓移植的细胞资源。我们的目标是1。定义收集和准备协议，与各种分娩环境兼容，2.定义冷冻保存方案，以允许长期储存胎盘，与当前脐带血储存工作兼容，以及3。定义与人类移植环境中的使用兼容的干细胞收获方案。PlaSalus将与奥克兰儿童医院研究所的专家以及由NIDDK资助的西雅图血液学核心卓越中心的癌症研究中心密切合作，为这一重要资源的商业化奠定基础。 公共卫生相关性：为了能够在骨髓移植中使用胎盘来源的造血干细胞和祖细胞，我们建议制定一个标准的协议，从人类足月胎盘收集和收获这些细胞。在这个第一阶段SBIR提案中，我们的目标是在一家小公司PlaSalus LLC和西雅图的Fred哈钦森癌症研究中心之间的合作努力中建立这种商业化技术。PlaSalus LLC已经获得了收获这些细胞的专有技术，我们的目标是独立确认，然后扩展儿童医院奥克兰研究所研究人员发表的令人兴奋的结果。我们设想这项技术将对骨髓移植实践产生重大影响，因为它将为需要干细胞替代的患者提供显着扩展的资源。

DESCRIPTION (provided by applicant): Unfortunately only a fraction of patients in need of transplantation with hematopoietic stem cells can benefit from this life saving treatment. Successful transplantation requires sufficient numbers of immunologically-matched stem cells, a highly limited resource. Cord blood collected after the birth of the baby, is a validated source of hematopoietic stem and progenitor cells (HSPC). However, while the utilization of umbilical cord blood for transplantation is expanding, the cellular content of each unit severely limits its application. Moreover, more than half of the cord blood units collected are not stored in public cord blood banks, as the stem cell count does not warrant storage for future use. PlaSalus aims to define protocols that will overcome these limitations, by the use of human term placenta. Using novel technology we propose to develop the placenta as novel source for HSPC to augment and drastically improve the current available cell resources for bone marrow transplant. We aim to 1. Define collection and preparation protocols, compatible with various child birth settings, 2. Define cryopreservation protocols to allow long-term storage of placenta, compatible with current cord blood storage efforts, and 3. Define stem cell harvesting protocols, compatible with use in human transplant settings. PlaSalus will closely collaborate with experts from Children's Hospital Oakland Research Institute, and the Cancer Research Centers NIDDK funded Core Center of Excellence in Hematology in Seattle, to set the stage for the commercialization of this important resource. PUBLIC HEALTH RELEVANCE: To enable the use of placental derived hematopoietic stem and progenitor cells in bone marrow transplant, we propose to develop a standard protocol for the collection and harvest of these cells from human term placentas. In this Phase 1 SBIR proposal we aim to establish this technology for commercialization in a collaborative effort between a small company, PlaSalus LLC, and the Fred Hutchinson Cancer Research Center in Seattle. PlaSalus LLC has acquired the proprietary technology for the harvest of these cells, and we aim to independently confirm, and then extend the exciting results as published by researchers at the Children's Hospital Oakland Research Institute. We envision that this technology will have a major impact on bone marrow transplant practices as it will provide a significantly expanded resource for patients in need of a stem cell replacement.